Formed by industry-experienced executives with extensive expertise and proven track records in Neonatal / Pediatric and similar Orphan Drug ânicheâ markets, Advent Therapeutics is structured to address serious unmet medical needs facing underserved populations in that space. Taking novel advantage of targeted already commercially-available or late-stage therapeutic opportunities â A Platform Approach to serving the most fragile patients - the firm's lead product is a proprietary, optimized Vitamin A Parenteral that can significantly reduce the incidence of neonatal BPD, a serious, costly respiratory disorder afflicting at-risk premature in
